8-KThe WireStrategic
Results of Operations
Filed May 7, 2026 · 1mo ago · Accession 0001193125-26-210428
Plain English
Silence Therapeutics plc announced its first quarter 2026 financial results and business highlights, including updates on its clinical trials for divesiran and SLN312. The company reported a net loss of $15.0 million for the quarter ended March 31, 2026.
Filing details
- Company
- Silence Therapeutics plc
- Ticker
- SLN
- CIK
- 1479615
- Form type
- 8-K
- Filing date
- May 7, 2026
- Report date
- May 7, 2026
- Document
- sln-20260507.htm
- Size
- 424 KB